JP2010519181A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010519181A5 JP2010519181A5 JP2009548468A JP2009548468A JP2010519181A5 JP 2010519181 A5 JP2010519181 A5 JP 2010519181A5 JP 2009548468 A JP2009548468 A JP 2009548468A JP 2009548468 A JP2009548468 A JP 2009548468A JP 2010519181 A5 JP2010519181 A5 JP 2010519181A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- amino
- alkyl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 4- (2- (2-propylpyridin-4-yl) thiazol-4-yl) phenyl Chemical group 0.000 claims description 242
- 125000001072 heteroaryl group Chemical group 0.000 claims description 160
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 160
- 150000001408 amides Chemical class 0.000 claims description 144
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 120
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims description 120
- 125000000304 alkynyl group Chemical group 0.000 claims description 120
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 102
- 239000000203 mixture Substances 0.000 claims description 99
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims description 96
- 125000005418 aryl aryl group Chemical group 0.000 claims description 96
- 229910052757 nitrogen Inorganic materials 0.000 claims description 74
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 72
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 72
- 125000001475 halogen functional group Chemical group 0.000 claims description 72
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 72
- 238000006467 substitution reaction Methods 0.000 claims description 64
- 125000003118 aryl group Chemical group 0.000 claims description 52
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 48
- 229910052717 sulfur Inorganic materials 0.000 claims description 48
- 239000011593 sulfur Substances 0.000 claims description 48
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 46
- 125000000217 alkyl group Chemical group 0.000 claims description 30
- 229910052760 oxygen Inorganic materials 0.000 claims description 26
- 239000001301 oxygen Substances 0.000 claims description 26
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 26
- LSNNMFCWUKXFEE-UHFFFAOYSA-L Sulphite Chemical group [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 24
- 125000005024 alkenyl aryl group Chemical group 0.000 claims description 24
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 24
- 150000008052 alkyl sulfonates Chemical group 0.000 claims description 24
- 125000005025 alkynylaryl group Chemical group 0.000 claims description 24
- 125000004367 cycloalkylaryl group Chemical group 0.000 claims description 24
- 150000003457 sulfones Chemical group 0.000 claims description 24
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical group OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 24
- 150000003462 sulfoxides Chemical group 0.000 claims description 24
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 16
- 150000001721 carbon Chemical class 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 208000008466 Metabolic Disease Diseases 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 12
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 12
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 12
- 125000003107 substituted aryl group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 claims description 10
- UIQZGUHSTKZKGY-UHFFFAOYSA-N 4-(2-methoxyphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C(=CC=CC=2)OC)=C1 UIQZGUHSTKZKGY-UHFFFAOYSA-N 0.000 claims description 8
- GOKVUOGCZQKXQS-UHFFFAOYSA-N N-propan-2-yl-4-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]aniline Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(NC(C)C)=CC=2)=C1 GOKVUOGCZQKXQS-UHFFFAOYSA-N 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 8
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 8
- 125000004426 substituted alkynyl group Chemical group 0.000 claims description 8
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 8
- HFSRZCFVFOUVKU-UHFFFAOYSA-N 3-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]phenol Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=C(O)C=CC=2)=C1 HFSRZCFVFOUVKU-UHFFFAOYSA-N 0.000 claims description 6
- VYYMYRPKZDHXOO-UHFFFAOYSA-N 4-(2,4-difluorophenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C(=CC(F)=CC=2)F)=C1 VYYMYRPKZDHXOO-UHFFFAOYSA-N 0.000 claims description 6
- OXTHFCVLLNTNRZ-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-(3,4-dimethoxyphenyl)-1,3-thiazole Chemical compound C1=C(OC)C(OC)=CC=C1C1=NC(C=2C=CC(Cl)=CC=2)=CS1 OXTHFCVLLNTNRZ-UHFFFAOYSA-N 0.000 claims description 6
- QKFIOIFLEOWEFH-UHFFFAOYSA-N 4-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]aniline Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(N)=CC=2)=C1 QKFIOIFLEOWEFH-UHFFFAOYSA-N 0.000 claims description 6
- UBVHKWIDYFYLLR-UHFFFAOYSA-N 4-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]phenol Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(O)=CC=2)=C1 UBVHKWIDYFYLLR-UHFFFAOYSA-N 0.000 claims description 6
- LZVRJUVBTQEBPU-UHFFFAOYSA-N N-[4-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]phenyl]acetamide Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(NC(C)=O)=CC=2)=C1 LZVRJUVBTQEBPU-UHFFFAOYSA-N 0.000 claims description 6
- 208000008589 Obesity Diseases 0.000 claims description 6
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 6
- 235000020824 obesity Nutrition 0.000 claims description 6
- 230000037361 pathway Effects 0.000 claims description 6
- NJCQOVROHVLZKB-UHFFFAOYSA-N 2-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]phenol Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C(=CC=CC=2)O)=C1 NJCQOVROHVLZKB-UHFFFAOYSA-N 0.000 claims description 4
- UBPWKUGAPZVWQE-UHFFFAOYSA-N 4-(3-methoxyphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=C(OC)C=CC=2)=C1 UBPWKUGAPZVWQE-UHFFFAOYSA-N 0.000 claims description 4
- VJLPOVIHSNLTQX-UHFFFAOYSA-N 4-(4-bromophenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(Br)=CC=2)=C1 VJLPOVIHSNLTQX-UHFFFAOYSA-N 0.000 claims description 4
- RJCFNQZVFUMORB-UHFFFAOYSA-N 4-(4-methylphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole;hydrobromide Chemical compound Br.C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(C)=CC=2)=C1 RJCFNQZVFUMORB-UHFFFAOYSA-N 0.000 claims description 4
- 206010012601 Diabetes mellitus Diseases 0.000 claims description 4
- OWAXXHRQPWGNTG-UHFFFAOYSA-N N-[4-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]phenyl]methanesulfonamide Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(NS(C)(=O)=O)=CC=2)=C1 OWAXXHRQPWGNTG-UHFFFAOYSA-N 0.000 claims description 4
- BAQOAQCINMPNGC-UHFFFAOYSA-N N-benzyl-4-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]aniline Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(NCC=3C=CC=CC=3)=CC=2)=C1 BAQOAQCINMPNGC-UHFFFAOYSA-N 0.000 claims description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atoms Chemical group 0.000 claims description 4
- 230000037213 diet Effects 0.000 claims description 4
- 235000005911 diet Nutrition 0.000 claims description 4
- 238000002651 drug therapy Methods 0.000 claims description 4
- 238000000554 physical therapy Methods 0.000 claims description 4
- 101710043414 SREBF1 Proteins 0.000 claims description 3
- 102100014920 SREBF1 Human genes 0.000 claims description 3
- 101710043417 SREBF2 Proteins 0.000 claims description 3
- 102100014921 SREBF2 Human genes 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- GGNIKGLUPSHSBV-UHFFFAOYSA-N 1,3-thiazole-5-carboxamide Chemical compound NC(=O)C1=CN=CS1 GGNIKGLUPSHSBV-UHFFFAOYSA-N 0.000 claims description 2
- OHCBMYMUPIIOHV-UHFFFAOYSA-N 2-(2-propylpyridin-4-yl)-4-thiophen-2-yl-1,3-thiazole Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2SC=CC=2)=C1 OHCBMYMUPIIOHV-UHFFFAOYSA-N 0.000 claims description 2
- CMUTYHWKASVOFO-UHFFFAOYSA-N 4-(2-chlorophenyl)-2-phenyl-1,3-thiazole Chemical compound ClC1=CC=CC=C1C1=CSC(C=2C=CC=CC=2)=N1 CMUTYHWKASVOFO-UHFFFAOYSA-N 0.000 claims description 2
- FYCNBEGGRGPPBC-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=C(Cl)C(Cl)=CC=2)=C1 FYCNBEGGRGPPBC-UHFFFAOYSA-N 0.000 claims description 2
- SXQHWZZWEJUUDI-UHFFFAOYSA-N 4-(4-bromophenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole-5-carboxylic acid Chemical compound C1=NC(CCC)=CC(C=2SC(=C(N=2)C=2C=CC(Br)=CC=2)C(O)=O)=C1 SXQHWZZWEJUUDI-UHFFFAOYSA-N 0.000 claims description 2
- ZNMIYSUPNOQXPL-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-(2-ethylpyridin-4-yl)-1,3-thiazole Chemical compound C1=NC(CC)=CC(C=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 ZNMIYSUPNOQXPL-UHFFFAOYSA-N 0.000 claims description 2
- QAIDAYZZJYOOJH-UHFFFAOYSA-N 4-(4-chlorophenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(Cl)=CC=2)=C1 QAIDAYZZJYOOJH-UHFFFAOYSA-N 0.000 claims description 2
- QKZNZFDVQQFDLV-UHFFFAOYSA-N 4-(4-fluorophenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(F)=CC=2)=C1 QKZNZFDVQQFDLV-UHFFFAOYSA-N 0.000 claims description 2
- UVUVXLDIFQWHBY-UHFFFAOYSA-N 4-(4-methoxyphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(OC)=CC=2)=C1 UVUVXLDIFQWHBY-UHFFFAOYSA-N 0.000 claims description 2
- SKHJXKHKCQDSOX-UHFFFAOYSA-N 4-(4-methoxyphenyl)-2-pyridin-4-yl-1,3-thiazole Chemical compound C1=CC(OC)=CC=C1C1=CSC(C=2C=CN=CC=2)=N1 SKHJXKHKCQDSOX-UHFFFAOYSA-N 0.000 claims description 2
- FCBWDNYFAULZCS-UHFFFAOYSA-N 4-(4-methylphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole-5-carboxylic acid Chemical compound C1=NC(CCC)=CC(C=2SC(=C(N=2)C=2C=CC(C)=CC=2)C(O)=O)=C1 FCBWDNYFAULZCS-UHFFFAOYSA-N 0.000 claims description 2
- RGQZKXSQOVPMHZ-UHFFFAOYSA-N 4-(4-methylphenyl)-2-phenyl-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=CSC(C=2C=CC=CC=2)=N1 RGQZKXSQOVPMHZ-UHFFFAOYSA-N 0.000 claims description 2
- WHGCQPQZQBCMTM-UHFFFAOYSA-N 4-(4-methylphenyl)-2-pyridin-4-yl-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=CSC(C=2C=CN=CC=2)=N1 WHGCQPQZQBCMTM-UHFFFAOYSA-N 0.000 claims description 2
- PSIIDDOTVGEEHU-UHFFFAOYSA-N 4-methyl-N-[4-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]phenyl]benzenesulfonamide Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(NS(=O)(=O)C=3C=CC(C)=CC=3)=CC=2)=C1 PSIIDDOTVGEEHU-UHFFFAOYSA-N 0.000 claims description 2
- YDCHGQNVVRRQLA-UHFFFAOYSA-N 4-phenyl-2-(2-propylpyridin-4-yl)-1,3-thiazole Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC=CC=2)=C1 YDCHGQNVVRRQLA-UHFFFAOYSA-N 0.000 claims description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- 208000008787 Cardiovascular Disease Diseases 0.000 claims description 2
- 239000005973 Carvone Substances 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 206010062060 Hyperlipidaemia Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- FMHQDMWHNYEVMV-UHFFFAOYSA-N N-(cyclopropylmethyl)-4-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]aniline Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(NCC3CC3)=CC=2)=C1 FMHQDMWHNYEVMV-UHFFFAOYSA-N 0.000 claims description 2
- RNMWGJXKUNRKSO-UHFFFAOYSA-N N-[4-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]phenyl]quinoline-8-sulfonamide Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(NS(=O)(=O)C=3C4=NC=CC=C4C=CC=3)=CC=2)=C1 RNMWGJXKUNRKSO-UHFFFAOYSA-N 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000003542 behavioural Effects 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- JKELRKVYOHHCPO-UHFFFAOYSA-N methyl 4-(4-methylphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole-5-carboxylate Chemical compound C1=NC(CCC)=CC(C=2SC(=C(N=2)C=2C=CC(C)=CC=2)C(=O)OC)=C1 JKELRKVYOHHCPO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- ATBCYIUPIXGWGZ-UHFFFAOYSA-N tert-butyl N-[4-[2-(2-propylpyridin-4-yl)-1,3-thiazol-4-yl]phenyl]carbamate Chemical compound C1=NC(CCC)=CC(C=2SC=C(N=2)C=2C=CC(NC(=O)OC(C)(C)C)=CC=2)=C1 ATBCYIUPIXGWGZ-UHFFFAOYSA-N 0.000 claims description 2
- KEAAJYWVSDRJIV-UHFFFAOYSA-N 4-phenyl-2-(2-propylpyridin-4-yl)-1,3-thiazole-5-carboxylic acid Chemical compound C1=NC(CCC)=CC(C=2SC(=C(N=2)C=2C=CC=CC=2)C(O)=O)=C1 KEAAJYWVSDRJIV-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88799407P | 2007-02-02 | 2007-02-02 | |
US60/887,994 | 2007-02-02 | ||
US1231007P | 2007-12-07 | 2007-12-07 | |
US61/012,310 | 2007-12-07 | ||
PCT/US2008/052778 WO2008097835A2 (en) | 2007-02-02 | 2008-02-01 | Compositions and methods for the treatment of metabolic disorders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014005460A Division JP5878937B2 (ja) | 2007-02-02 | 2014-01-15 | 代謝障害を処置するための組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010519181A JP2010519181A (ja) | 2010-06-03 |
JP2010519181A5 true JP2010519181A5 (ru) | 2012-03-08 |
JP5461197B2 JP5461197B2 (ja) | 2014-04-02 |
Family
ID=39682342
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009548468A Active JP5461197B2 (ja) | 2007-02-02 | 2008-02-01 | 代謝障害を処置するための組成物および方法 |
JP2014005460A Expired - Fee Related JP5878937B2 (ja) | 2007-02-02 | 2014-01-15 | 代謝障害を処置するための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014005460A Expired - Fee Related JP5878937B2 (ja) | 2007-02-02 | 2014-01-15 | 代謝障害を処置するための組成物および方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US8207196B2 (ru) |
EP (1) | EP2120580B1 (ru) |
JP (2) | JP5461197B2 (ru) |
CN (1) | CN101674730B (ru) |
AU (1) | AU2008214095B2 (ru) |
CA (1) | CA2677264C (ru) |
WO (1) | WO2008097835A2 (ru) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9233941B2 (en) * | 2007-02-02 | 2016-01-12 | Baylor College Of Medicine | Methods and compositions for the treatment of body weight related disorders |
US9212179B2 (en) * | 2007-02-02 | 2015-12-15 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
WO2008097835A2 (en) * | 2007-02-02 | 2008-08-14 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
US9187485B2 (en) * | 2007-02-02 | 2015-11-17 | Baylor College Of Medicine | Methods and compositions for the treatment of cancer and related hyperproliferative disorders |
EP2250160B1 (en) | 2008-01-25 | 2015-11-11 | Millennium Pharmaceuticals, Inc. | Thiophenes and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors |
UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
CN102395585A (zh) | 2009-01-30 | 2012-03-28 | 米伦纽姆医药公司 | 杂芳基化合物和其作为pi3k抑制剂的用途 |
US9090601B2 (en) | 2009-01-30 | 2015-07-28 | Millennium Pharmaceuticals, Inc. | Thiazole derivatives |
US8796314B2 (en) | 2009-01-30 | 2014-08-05 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
WO2011140296A1 (en) | 2010-05-05 | 2011-11-10 | Infinity Pharmaceuticals | Triazoles as inhibitors of fatty acid synthase |
EP3159331A1 (en) | 2010-05-05 | 2017-04-26 | Infinity Pharmaceuticals, Inc. | Tetrazolones as inhibitors of fatty acid synthase |
JP2013533318A (ja) | 2010-08-11 | 2013-08-22 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | ヘテロアリールおよびその使用 |
WO2012021611A1 (en) | 2010-08-11 | 2012-02-16 | Millennium Pharmaceuticals, Inc. | Heteroaryls and uses thereof |
AR082665A1 (es) | 2010-08-11 | 2012-12-26 | Millennium Pharm Inc | Derivados heteroarilicos inhibidores de quinasas pi3k, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos proliferativos, inflamatorios y/o cardiovasculares |
EP2616441B1 (en) * | 2010-09-17 | 2019-08-07 | Purdue Pharma L.P. | Pyridine compounds and the uses thereof |
EP2625294A4 (en) * | 2010-10-07 | 2014-03-26 | Univ Columbia | METHOD OF TREATING CANCER WITH P53 MUTATION |
SG189396A1 (en) | 2010-10-13 | 2013-05-31 | Millennium Pharm Inc | Heteroaryls and uses thereof |
CA2825306C (en) * | 2011-01-25 | 2019-02-26 | The Regents Of The University Of Michigan | Bcl-2/bcl-xl inhibitors and therapeutic methods using the same |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US20140364460A1 (en) * | 2012-01-18 | 2014-12-11 | The Trustees Of Columbia University In The City Of New York | USE OF FATOSTATIN FOR TREATING CANCER HAVING A p53 MUTATION |
WO2014004054A1 (en) | 2012-06-25 | 2014-01-03 | Thomas Jefferson University | Compositions and methods for treating cancer with aberrant lipogenic signaling |
US20140275178A1 (en) * | 2013-03-13 | 2014-09-18 | Musc Foundation For Research Development | Thiazole compounds, compositions and methods for treatment of degenerative diseases and disorders |
TR201809185T4 (tr) * | 2013-08-28 | 2018-07-23 | Medivation Tech Llc | Heterosiklik bileşikler ve kullanım yöntemleri. |
WO2015031710A1 (en) * | 2013-08-29 | 2015-03-05 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic and body weight related disorders |
BR112016018691A2 (pt) * | 2014-02-14 | 2017-08-08 | Univ British Columbia | Compostos do domínio de ligação ao dna (dbd) de receptor de andrógeno humano como terapêuticos e métodos para seu uso |
US9873689B2 (en) | 2014-11-07 | 2018-01-23 | Fgh Biotech, Inc. | Synthesis of fatostatin based polycyclic compounds |
WO2016105491A1 (en) * | 2014-12-23 | 2016-06-30 | Fgh Biotech | Compositions of fatostatin based heterocyclic compounds and uses thereof |
US10532987B2 (en) * | 2015-02-17 | 2020-01-14 | Guangzhou Institutes Of Biomedicine And Health, Chinese Academy Of Science | Compounds and methods for inducing browning of white adipose tissue |
EP3265457A1 (en) | 2015-03-04 | 2018-01-10 | Medivation Technologies LLC | Sterol regulatory element-binding proteins (srebps) inhibitors |
EP3265088A1 (en) | 2015-03-04 | 2018-01-10 | Medivation Technologies LLC | Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance |
US11117939B2 (en) * | 2015-05-29 | 2021-09-14 | University of Sasketchewan | Polypeptides and antibodies to treat skin conditions associated with overproduction of sebum |
WO2017079721A1 (en) * | 2015-11-06 | 2017-05-11 | The Children's Hospital Of Philadelphia | Compositions and methods for the treatment of fatty acid metabolism disorders |
JP6931695B2 (ja) | 2016-04-29 | 2021-09-08 | エフジーエイチ バイオテック,インコーポレーテッド | 疾患の治療のための二置換ピラゾール化合物 |
ES2932187T3 (es) * | 2016-09-07 | 2023-01-16 | Fgh Biotech Inc | Compuestos de pirazol disustituidos para el tratamiento de enfermedades |
KR101869308B1 (ko) * | 2017-02-28 | 2018-06-20 | 대구가톨릭대학교산학협력단 | Srebp-1 디코이 올리고디옥시뉴클레오티드 및 이를 유효성분으로 함유하는 지방간 질환의 예방 또는 치료용 약학 조성물 |
US11944598B2 (en) | 2017-12-19 | 2024-04-02 | Axcess Global Sciences, Llc | Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer |
WO2019148125A1 (en) | 2018-01-29 | 2019-08-01 | Capulus Therapeutics, Llc | Srebp inhibitors comprising a 6-membered central ring |
WO2020132700A1 (en) * | 2018-12-21 | 2020-06-25 | Fgh Biotech Inc. | Methods of using inhibitors of srebp in combination with niclosamide and analogs thereof |
WO2020159889A1 (en) * | 2019-01-28 | 2020-08-06 | Capulus Therapeutics, Llc | Srebp inhibitors comprising a thiophene central ring |
US11950616B2 (en) | 2019-06-21 | 2024-04-09 | Axcess Global Sciences, Llc | Non-vasoconstricting energy-promoting compositions containing ketone bodies |
WO2021035031A1 (en) * | 2019-08-21 | 2021-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibitors of phospholipid synthesis and methods of use |
WO2021154735A1 (en) * | 2020-01-27 | 2021-08-05 | Capulus Therapeutics, Llc | Srebp inhibitors comprising a thiophene central ring |
US20220062216A1 (en) * | 2020-08-26 | 2022-03-03 | Axcess Global Sciences, Llc | Compositions and methods for increasing lean-to-fat mass ratio |
WO2023230495A2 (en) * | 2022-05-25 | 2023-11-30 | Amgen Inc. | Rnai constructs for inhibiting scap expression and methods of use thereof |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4791200A (en) * | 1987-06-22 | 1988-12-13 | Ortho Pharmaceutical Corporation | 2-substituted-4-aryl-substituted thiazoles |
US5725871A (en) | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
DE69133471T2 (de) * | 1990-11-30 | 2006-05-11 | Otsuka Pharmaceutical Co., Ltd. | Azolderivate und ihre Verwendung als Inhibitoren von Superoxidradikalen |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
JPH04282326A (ja) * | 1991-03-08 | 1992-10-07 | Yuki Gosei Kogyo Co Ltd | 非対称な三環系化合物の製造法 |
DK0590060T3 (da) | 1991-06-21 | 1998-05-11 | Univ Cincinnati | Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling |
US5756353A (en) | 1991-12-17 | 1998-05-26 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol-and liposome-based delivery |
EP0641192B1 (en) | 1992-05-18 | 1997-07-23 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
WO1994022846A1 (en) * | 1993-03-30 | 1994-10-13 | Pfizer Inc. | Compounds enhancing antitumor activity of other cytotoxic agents |
US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
MY128323A (en) | 1996-09-30 | 2007-01-31 | Otsuka Pharma Co Ltd | Thiazole derivatives for inhibition of cytokine production and of cell adhesion |
JPH1179993A (ja) * | 1997-09-05 | 1999-03-23 | Sumitomo Pharmaceut Co Ltd | 免疫抑制剤 |
JPH11186479A (ja) | 1997-12-22 | 1999-07-09 | Toyo Commun Equip Co Ltd | 放熱板付き表面実装部品 |
JP2000080086A (ja) * | 1998-07-01 | 2000-03-21 | Takeda Chem Ind Ltd | レチノイド関連受容体機能調節剤 |
ID29247A (id) | 1998-07-01 | 2001-08-16 | Takeda Chemical Industries Ltd | Bahan pengatur fungsi reseptor retinoid |
GB9916757D0 (en) * | 1999-07-17 | 1999-09-15 | Glaxo Group Ltd | Method |
US6537514B1 (en) | 1999-10-26 | 2003-03-25 | Praxair Technology, Inc. | Method and apparatus for producing carbon dioxide |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
CA2431171A1 (en) | 2000-12-08 | 2002-06-13 | Takeda Chemical Industries, Ltd. | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof |
BR0207390A (pt) * | 2001-02-21 | 2004-10-13 | Nps Pharma Inc | Compostos, composições farmacêuticas e métodos de tratatamento de doença associada a ativação e a ativação do grupo i mg1ur |
US7153889B2 (en) * | 2002-11-12 | 2006-12-26 | Abbott Laboratories | Bicyclic-substituted amines as histamine-3 receptor ligands |
WO2004110998A1 (en) * | 2003-05-16 | 2004-12-23 | Ambit Biosciences Corporation | Pyrrole compounds and uses thereof |
US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
CN101213194A (zh) | 2004-08-03 | 2008-07-02 | 惠氏公司 | 可用于治疗心血管疾病的吲唑化合物 |
AR051597A1 (es) * | 2004-11-01 | 2007-01-24 | Merck & Co Inc | Moduladores de los receptores de estrogeno |
WO2006080406A1 (ja) | 2005-01-28 | 2006-08-03 | Taisho Pharmaceutical Co., Ltd. | 三環性化合物 |
US20090291988A1 (en) * | 2005-06-14 | 2009-11-26 | Renata Oballa | Reversible Inhibitors of Monoamine Oxidase A and B |
WO2007001973A1 (en) | 2005-06-28 | 2007-01-04 | Astrazeneca Ab | New use |
US8642278B2 (en) * | 2005-11-22 | 2014-02-04 | University Of South Florida | Inhibition of cell proliferation |
WO2008097835A2 (en) * | 2007-02-02 | 2008-08-14 | Baylor College Of Medicine | Compositions and methods for the treatment of metabolic disorders |
WO2013052588A1 (en) * | 2011-10-04 | 2013-04-11 | Dow Corning Corporation | Iron(ii) containing complex and condensation reaction catalysts, methods for preparing the catalysts, and compositions containing the catalysts |
-
2008
- 2008-02-01 WO PCT/US2008/052778 patent/WO2008097835A2/en active Application Filing
- 2008-02-01 CN CN200880008035.2A patent/CN101674730B/zh active Active
- 2008-02-01 CA CA2677264A patent/CA2677264C/en active Active
- 2008-02-01 EP EP08728809.8A patent/EP2120580B1/en active Active
- 2008-02-01 AU AU2008214095A patent/AU2008214095B2/en not_active Ceased
- 2008-02-01 US US12/024,530 patent/US8207196B2/en active Active
- 2008-02-01 JP JP2009548468A patent/JP5461197B2/ja active Active
-
2012
- 2012-05-31 US US13/484,702 patent/US8927578B2/en active Active
- 2012-05-31 US US13/484,685 patent/US8778976B2/en active Active
-
2014
- 2014-01-15 JP JP2014005460A patent/JP5878937B2/ja not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010519181A5 (ru) | ||
KR101179087B1 (ko) | 인간 단백질 티로신 포스파타아제 억제제 및 이용 방법 | |
RU2461551C2 (ru) | Азолкарбоксамидное соединение или его фармацевтически приемлемая соль | |
KR101155365B1 (ko) | 인간 단백질 타이로신 포스파타아제 억제제 및 사용 방법 | |
RU2009118602A (ru) | Производное индола | |
KR20080034436A (ko) | 암 치료에 사용되는 티아졸 유도체 및 유사체 | |
JP2009513563A5 (ru) | ||
JP2010506825A5 (ru) | ||
JP2004534035A5 (ru) | ||
RU2013143028A (ru) | Тиазолилфенилбензолсульфонамидопроизводные в качестве ингибиторов киназ | |
WO2007123269A1 (ja) | アゾールカルボキサミド誘導体 | |
RU2010142229A (ru) | Производное циклопентилакриламида | |
JP2006516251A5 (ru) | ||
JP2016534124A5 (ru) | ||
RU2004129285A (ru) | Производные тиазола в качестве антагонистов рецептора npy | |
RU2015126293A (ru) | Производные тиазола в качестве ингибиторов тирозинкиназы брутона | |
RU2435763C2 (ru) | Ингибиторы тирозинфосфатазы белка человека и способы применения | |
WO2006125285B1 (en) | Insulin sensitization to slow down pubertal tempo and to augment pubertal growth | |
JP2004513923A5 (ru) | ||
ZA200505350B (en) | Treatment of cancer with 2-deoxyglucose Acylaminothiazole derivatives, preparation method thereof and use of same as beta-amyloid peptide production inhibitors | |
HRP20110716T1 (hr) | Aril dikarboksamidi |